WAT Med Passes the BSI Social Responsibility Review

December 26, 2019

WAT Med Passes the BSI Social Responsibility Review

In October 2018, Amazon launched the Amazon Accelerator Program, hoping to cultivate more exclusive brands for the platform. The brands joining the accelerator program are partners chosen by Amazon and would obtain professional assistance in marketing, logistics and inventory management. One of the prerequisites for joining the brand accelerator program is to pass the Social Responsibility Audit. Amazon’s Supplier Code of Conduct requires suppliers demonstrate ethical and safe working conditions in operating facilities.

WAT Med specializes in the development of precise, wearable, and intelligent medical devices. It has a research and development center in Canada, with top personnel in the medical field and a complete medical device manufacturing and quality management system. Since its establishment in 2017, the company has obtained 61 patents from the United States, the European Union, Japan and registered trademarks many countries worldwide. The company will continue to launch future innovative products and make long-lasting contributions in the healthcare landscape.

EmeTerm has obtained medical device certification from the United States, Canada, Australia, Israel and the European Union. EmeTerm uses a targeted nerve regulation mechanism to release accurate electrical pulse signals to the median nerve. It relieves vomiting during chemotherapy, post-operation, and pregnancy. The product is free from side effects such as drowsiness, tremor and many others caused by drugs. It can be used repeatedly, has high waterproof grade, and has a battery life of up to 9 hours of continuous use. Consumer satisfaction reached 92%.

HeadaTerm is another product developed by WAT Med, which relieves primary headache, insomnia, tension, depression and facial neuralgia caused by primary headache. With specific low-frequency electrical pulses, it stimulates coarse nerve fibers, the afferent center, and activates the descending inhibition system. This activates the opioid mechanism to release endorphins and achieve therapeutic effects.

Both products are well-received by consumers in many countries, and have obtained medical device registration certificates from the United States, Europe, Canada and Australia. WAT Med ensures that their products meet their high-quality standards and would always take valuable user feedback into consideration when making improvements to their products. In November 2019, WAT Med successfully passed the BSI Social Responsibility Review (Sedex 2P), thus reaching an important part in joining the Amazon Accelerator program.

EmeTerm of WAT Med has been widely recognized and supported by consumers since it entered Amazon in 2017. Now invited to join Amazon’s accelerator program in 2019, Amazon’s advantages in marketing and logistics will surely support EmeTerm’s future development, and write a new chapter in WAT Med’s service for consumer.

Reference:

  1. https://www.amazon.com/b?ie=UTF8&node=17882322011
  2. https://sustainability.aboutamazon.com/social-responsibility
  3. https://research-methodology.net/amazon-corporate-social-responsibility/
  4. https://www.qima.com/smeta-audit


Leave a comment

Comments will be approved before showing up.